Why Miracell’s SMART M-CELL FDA clearance could reshape the PRP and BMAC device market
Miracell has won FDA 510(k) clearance for SMART M-CELL. Read what it changes for PRP, BMAC, adoption, and regenerative medicine competition.
Can Aspect Biosystems turn government-backed biomanufacturing into a real regenerative medicine advantage?
Aspect Biosystems has secured a $280 million Canada-backed push in regenerative medicine. Read what it means for cellular therapy scale-up.
How XellSmart’s expanding IND portfolio is shaping the emerging market for CNS cell therapies
XellSmart’s iPSC-derived neuron therapy enters MSA-P trials after FDA and NMPA clearances. Discover what this means for regenerative neurology.
What Matricelf’s Parkinson’s spinout reveals about the future of cell based neurodegeneration therapies
Matricelf plans a subsidiary to commercialize its Parkinson’s therapy platform. Discover what this move signals for regenerative medicine and neurology innovation.
What Longeveron Inc.’s Phase 2b results mean for regenerative medicine in aging populations
Longeveron Inc. publishes Phase 2b laromestrocel data in frailty. Explore what it means for stem cell therapy and regulatory next steps.
What StimLabs’ DermaForm approval reveals about the future of regenerative wound care
StimLabs has secured FDA clearance for DermaForm, expanding its wound care portfolio. Find out what this changes for clinicians and the market.
How United Therapeutics is betting on scaffold-based liver support in high-mortality ALF
United Therapeutics’ miroliverELAP showed positive phase 1 safety results in acute liver failure. Find out what this could mean for future liver support strategies.
Landmark FDA nod gives MSC developers long-awaited quality benchmark for clinical use
The FDA has recognized Tasly’s 3P assay as the first quality control standard for MSCs. Find out what this changes for developers and regulators.
Replacing microbiota rejuvenates aging gut tissue: What new mouse data means for regenerative GI therapies
A mouse study suggests young microbiota can rejuvenate aging gut tissue. Find out what this could mean for regenerative GI therapies and IBD care.
BioStem acquires Neox and Clarix as BioTissue refocuses on eye care therapies
BioTissue exits surgical wound care to refocus on eye care innovation, selling Neox and Clarix lines to BioStem. Find out what this deal changes in MedTech.